First, let’s explain what Doxy is. Doxy is short for doxycycline, a broad-spectrum antibiotic that has gained attention as an effective tool for preventing certain sexually transmitted infections (STIs). Recent studies have shown that taking this medication within 72 hours after condomless sex can significantly reduce the risk of infection with chlamydia and syphilis and, in some settings, gonorrhoea.
Difference Between DoxyPEP and DoxyPrEP
Unlike pre-exposure prophylaxis for HIV (PrEP), DoxyPEP (post-exposure prophylaxis) involves taking 200 mg of doxycycline after a potential exposure to an STI. The current recommendation is to take the dose as soon as possible, ideally within 24 hours and no later than 72 hours after condomless sex.
DoxyPrEP, which would involve taking doxycycline daily before exposure, is not currently a recommended prevention strategy. There is currently not enough evidence to support daily doxycycline as PrEP, and the World Health Organization does not recommend this approach.
Pros and Cons
Using doxycycline as prophylaxis has advantages and disadvantages that should be considered before starting it.
Advantages:
- Studies have shown that DoxyPEP can significantly reduce the risk of chlamydia and syphilis, particularly among men who have sex with men and transgender women.
- It offers an additional prevention option for people at higher risk of acquiring STIs, particularly those with recent or recurrent STIs and ongoing risk of exposure.
Disadvantages:
- The use of antibiotics can contribute to antimicrobial resistance, potentially making future infections more difficult to treat. This is one of the main concerns surrounding DoxyPEP.
- Common side effects include nausea, stomach upset, diarrhoea and increased sensitivity to sunlight.
- To minimise side effects, users should follow the instructions provided by their healthcare professional regarding how to take the medication.
Availability and Medical Advice
DoxyPEP is becoming available in an increasing number of countries and healthcare settings, but access and prescribing guidelines vary depending on the country. It is important to speak with a healthcare professional to determine whether DoxyPEP is an appropriate option.
The World Health Organization currently recommends that DoxyPEP may be offered to men who have sex with men and transgender women, particularly those with a recent or recurrent STI and ongoing risk of exposure. WHO does not currently recommend DoxyPEP for other populations.
For more information about DoxyPEP and DoxyPrEP, consult reliable sources such as the World Health Organization and local public health authorities.
Note: Prevention through safer sex practices, including condom use and regular STI testing, remains essential for maintaining a healthy and responsible sex life. DoxyPEP is an additional prevention tool and does not protect against HIV or all other STIs.
This article was originally published by dezanove.pt
